推荐产品
产品名称
吉非替尼, ≥98% (HPLC)
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 10 mg/mL, clear
储存温度
room temp
SMILES字符串
COC(C=C(N=CN=C1NC2=CC(Cl)=C(F)C=C2)C1=C3)=C3OCCCN4CCOCC4
InChI
1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InChI key
XGALLCVXEZPNRQ-UHFFFAOYSA-N
基因信息
human ... EGFR(1956)
正在寻找类似产品? 访问 产品对比指南
应用
吉非替尼已用于：
- 研究其在子宫内膜癌治疗中的有效应用
- 细胞增殖、细胞周期和细胞凋亡试验
- 细胞活力测定和集落形成试验
生化/生理作用
吉非替尼是一种选择性表皮生长因子受体酪氨酸激酶 (EGFR TK) 抑制剂。吉非替尼具有抗肿瘤活性，已被批准用于治疗非小细胞肺癌 (NSCLC)。
吉非替尼对 EGFR 酪氨酸激酶结构域中 ATP（三磷酸腺苷）结合站点的亲和力高于 ATP。因此，已知吉非替尼可抑制子宫内膜癌的进展。
吉非替尼对 EGFR 酪氨酸激酶结构域中 ATP（三磷酸腺苷）结合站点的亲和力高于 ATP。因此，已知吉非替尼可抑制子宫内膜癌的进展。
警示用语：
Danger
危险分类
Acute Tox. 4 Oral - Aquatic Chronic 1 - Carc. 2 - Eye Dam. 1 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 Oral
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
其他客户在看
Brian S Bogdanowicz et al.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 23(3), 203-214 (2016-02-26)
Purpose The approval history, pharmacology, pharmacokinetics, clinical trials, efficacy, dosing recommendations, drug interactions, safety, place in therapy, and economic considerations of gefitinib are reviewed. Summary Lung cancer is one of the most commonly diagnosed cancers and is the leading cause
Baodan Yu et al.
Molecular medicine reports, 24(4) (2021-08-17)
Tyrosine kinase inhibitors, such as gefitinib, are currently widely used as targeted therapeutics for non‑small cell lung cancer (NSCLC). Although drug resistance has become a major obstacle to successful treatment, mechanisms underlying resistance to gefitinib remain unclear. Therefore, the present
Hisanori Isomura et al.
Cancer science, 112(4), 1614-1623 (2021-01-29)
We previously reported that ROR1 is a crucial downstream gene for the TTF-1/NKX2-1 lineage-survival oncogene in lung adenocarcinoma, while others have found altered expression of ROR1 in multiple cancer types. Accumulated evidence therefore indicates ROR1 as an attractive molecular target
Silencing of long non-coding RNA MIAT sensitizes lung cancer cells to gefitinib by epigenetically regulating miR-34a.
Fu Y, et al.
Frontiers in Pharmacology, 9, 82-82 (2018)
The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma.
Qiu M, et al.
Cancer Research, 78(11), 2839-2851 (2018)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持